title: A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost.
abstract: OBJECTIVE
  To conduct a 12-month prospective study on the occurrence of latanoprost-induced iridial pigmentation and eyelash change in Japanese patients with glaucoma
  
  
  METHODS
  Seventy-five patients (75 eyes) were enrolled in the study. Photographs of the iris and eyelashes were taken under identical conditions before and after treatment. Three glaucoma specialists assessed the iridial pigmentation/eyelash change independently with no knowledge of patient data. The effects of age, sex, concomitant medication, and type of glaucoma on iridial pigmentation/eyelash change were investigated, and intraocular pressure (IOP) reduction and iridocorneal angle pigmentation before and after latanoprost treatment were compared between patients with iridial pigmentation/eyelash change and patients without these changes.
  
  
  RESULTS
  The incidence of iridial pigmentation was 6.3% at 1 month, 15.7% at 3 months, 37.8% at 6 months, and 56.5% at 12 months. The incidence of eyelash change was 0% at 1 month, 33.8% at 3 months, 44.4% at 6 months, and 46.2% at 12 months. Latanoprost did not affect IOP reduction or iridocorneal angle pigmentation. No significant relationship between iridial pigmentation and eyelash change was observed. None of the investigated parameters except age affected the iridial pigmentation/eyelash change.
  
  
  CONCLUSIONS
  Iridial pigmentation and eyelash change occurred at a high frequency in long-term treatment with latanoprost in Japanese glaucoma patients.
authors.affiliation: Department of Ophthalmology, University of Yamanashi, Faculty of Medicine, Yamanashi, Tamaho, Japan.
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Chiba
authors.forename: Kenji
authors.initials: K
authors.lastname: Kashiwagi
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Ishijima
authors.forename: Mieko
authors.initials: M
authors.lastname: Furuichi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kogure
authors.forename: Keitetsu
authors.initials: K
authors.lastname: Abe
authors.forename: Nami
authors.initials: N
authors.lastname: Chiba
authors.forename: Shigeo
authors.initials: S
authors.lastname: Tsukahara
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000009:adverse effects*; D005127:Eye Color / Q000187:drug effects; D005140:Eyelashes / Q000187:drug effects*; D005260:Female; D005901:Glaucoma / Q000188:drug therapy; D006200:Hair Color / Q000187:drug effects; D006201:Hair Diseases / Q000139:chemically induced*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D007499:Iris Diseases / Q000139:chemically induced*; D000077338:Latanoprost; D008297:Male; D008548:Melanosis / Q000139:chemically induced*; D008875:Middle Aged; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects*
chemical_list: D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost